Replies to post #78 on Precision BioSciences Inc (DTIL)

[jondoeuk]

ALLO is working on a number of next-gen versions, including using CLLS's TALENs to insert the CAR into the TRAC locus. Also, signed a deal with Antion Bio for its miCAR constructs. This allows them to silence up to six genes simultaneously, and add multiple (up to four, such as a CAR) in a single step.

Moving to CRSP*, for next-gen, they have already locked in the design and edits (four or five). Now they are designing third-gen, which will have seven or eight edits. In addition, with their own facility in Framingham have automated parts of manufacturing, started to use machine learning plus translational data, and CRISPR screens https://aacrjournals.org/cancerres/article-abstract/81/13_Supplement/1537/667455/Abstract-1537-CD70-knockout-A-novel-approach-to

* Working with NKTX on three different products. One will combine CAR-NK plus CAR-T (both could target two different antigens), as well as two CAR-NK cell products, one of which will target CD70 https://www.abstractsonline.com/pp8/#!/10517/presentation/17731 https://www.abstractsonline.com/pp8/#!/10517/presentation/17730